HUTCHISON CHINA/S (NASDAQ:HCM) has been given an average recommendation of “Buy” by the six research firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $26.82.
HCM has been the topic of several research analyst reports. BidaskClub downgraded HUTCHISON CHINA/S from a “buy” rating to a “hold” rating in a research note on Saturday, December 22nd. Zacks Investment Research upgraded HUTCHISON CHINA/S from a “sell” rating to a “hold” rating in a research note on Wednesday, December 26th. ValuEngine downgraded HUTCHISON CHINA/S from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Deutsche Bank initiated coverage on HUTCHISON CHINA/S in a research note on Monday, March 4th. They set a “buy” rating and a $26.82 price target on the stock.
HUTCHISON CHINA/S stock traded down $0.16 during trading hours on Friday, hitting $30.35. 136,296 shares of the stock traded hands, compared to its average volume of 126,689. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.19 and a current ratio of 4.33. The company has a market cap of $4.05 billion, a PE ratio of -53.25 and a beta of 1.11. HUTCHISON CHINA/S has a 1 year low of $20.83 and a 1 year high of $39.68.
HUTCHISON CHINA/S Company Profile
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.
Recommended Story: What does cost of debt say about a company’s financial health?
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.